

# Depression...disturbed sleep...



75mg capsule

## Sinequan<sup>\*</sup>

brand of doxepin \* Trade Mark

### lifts depression... promotes restful sleep

- SEDATIVE ANTIDEPRESSANT
- ONCE NIGHTLY DOSAGE

**Indications:** depression with or without anxiety. **Contraindications:** glaucoma, urinary retention, hypersensitivity to the drug. **Side effects:** dry mouth and drowsiness are most commonly reported. **Precautions:** Sinequan may potentiate other compounds - e.g. monoamine oxidase inhibitors; not recommended in pregnancy or children under 12 years age. **Dosage:** range 30 mg to 300 mg daily in divided doses, up to 100 mg may be given as a single dose at night. **Packs and Basic N.H.S. Cost:** 10 mg capsules (PL 57/5032), pack of 100, £2.98; 25 mg capsules (PL 57/5033), pack of 100, £4.24; 50 mg capsules (PL 57/5034) pack of 100, £7.01; 75 mg capsules (PL 57/0133), pack of 60, £6.64.

Full information on request to the Company.



**PFIZER LIMITED**  
SANDWICH, KENT.

# Epilim<sup>®</sup>

sodium valproate

200 enteric-coated, 500 enteric-coated tablets; syrup.

Epilim is a powerful anticonvulsant capable of providing control for the majority of adults with tonic-clonic seizures or other epilepsies, including those not well controlled on previous treatments. Because it controls without sedation, Epilim allows many patients to lead full, normal lives.

#### Presentation

1. Epilim 200 enteric-coated. A lilac-coloured enteric-coated tablet containing 200mg sodium valproate
2. Epilim tablets. A white scored tablet containing 200mg sodium valproate
3. Epilim 500 enteric-coated. A lilac-coloured enteric-coated tablet containing 500mg sodium valproate.
4. Epilim Syrup. A red cherry-flavoured syrup containing 200mg sodium valproate per 5ml.

#### Indications

Epilepsy. In women of childbearing age, Epilim should be used only in severe cases or in those resistant to other treatment.

#### Dosage and Administration

To be taken with or after food, enteric-coated and plain tablets should be swallowed whole. Optimum dosage should be established using the 200mg enteric-coated tablet. Epilim 500 enteric-coated is recommended for patients requiring high dosages.

**Adults:** Dosage should start at 600mg/day, in divided doses, increasing by 200mg/day at three-day intervals until control is achieved. (Maximum Dose 2600mg/day).

In patients already receiving other therapy the same pattern should be followed. Dosage of barbiturates should be reduced as that of Epilim is increased, the respective dosages should be adjusted, during the stabilisation period, to give optimum control at the lowest possible combined-dose level, and it may be found possible to maintain control with Epilim alone.

Once known enzyme-inducers have been withdrawn, it may be possible to maintain seizure control on a reduced dose of Epilim. Although a method of measuring plasma levels is available, optimum dosage must ultimately be determined by seizure-control.

**Children over 20kg:** Initially 400mg/day in divided doses with spaced increases until control is achieved (usually in the range of 20-30mg/kg/day).

**Children under 20kg:** 20mg/kg of body weight per day, in severe cases, this may be increased up to 50mg/kg/day but should be undertaken only in patients in whom plasma valproate levels, clinical chemistry and haematological parameters can be monitored.

#### Contra-Indications, Warnings, etc.

Liver dysfunction, including hepatic failure resulting in fatalities has occurred in patients whose treatment included valproic acid or sodium valproate. The incidents occurred during the first six months of therapy, the period of maximum risk being 2-12 weeks. No deaths have occurred in patients receiving the drug continuously for more than 6 months.

Biochemical tests may not always become abnormal early in the evolution of hepatic failure; non-specific findings such as loss of seizure control, malaise, anorexia and vomiting, developing after a period of satisfactory Epilim treatment may alert the clinician to the possibility of hepatic damage.

Epilim should not be administered to patients with pre-existing hepatic dysfunction. All patients for whom treatment with Epilim is contemplated should have base line liver function assessed (including serum fibrinogen and albumin levels) prior to commencement of therapy. Liver function should be carefully monitored, particularly during the first six months of therapy, and when dosage is being titrated upwards. Patients with a prior history of liver disease or with severe or unusual seizure disorders, e.g. those accompanied by mental retardation and/or organic brain disease, should be followed particularly carefully. Transient elevations of liver enzymes are not uncommon during early treatment with Epilim, but, if elevations are accompanied by other evidence of hepatic dysfunction, especially raised serum bilirubin or lowered serum fibrinogen, then the drug should be immediately withdrawn.

Hyperammonaemia without hepatic damage can occur in patients during treatment with valproic acid or sodium valproate. This may manifest clinically as vomiting, ataxia and increasing clouding of consciousness. Should these symptoms occur, Epilim should be discontinued.

Valproic acid inhibits second stage of platelet aggregation. Reversible prolongation of bleeding time and thrombocytopenia have been reported. Spontaneous bruising or bleeding is an indication for withdrawal of medication pending investigations. Patients receiving Epilim should be monitored for platelet function before major surgery. Red cell hypoplasia and leucopenia have been reported. The blood picture returned to normal when the drug was discontinued. Pancreatitis has occurred in patients receiving valproic acid or sodium valproate. Patients experiencing acute abdominal pain should have serum amylase estimated.

Minor gastric irritation and, less frequently, nausea may occur at the start of treatment but these problems can usually be overcome by administering Epilim tablets or syrup with or after food, or by transferring the patient to the Epilim enteric-coated formulations. Transient hair loss has been noted in some patients. Regrowth normally begins within six months. Tremor has occasionally been observed at high dosage.

Oedema has been reported. Increase in alertness, appetite and weight may occur. **Combined medication:** Epilim is generally well tolerated in combination with other anti-epileptic agents; however, as interaction occurs between these compounds, it may sometimes be necessary to reduce the dosage of other drugs when adding Epilim to existing anti-convulsant therapy. Epilim may also potentiate the effect of monoamine oxidase inhibitors and other anti-depressants, and dosage of such compounds should be reduced.

**Diabetic patients:** Epilim may give false positives in urine testing for ketones. Care should be taken when treating diabetic patients with Epilim Syrup which contains 3.6g sucrose per 5ml.

**Women of childbearing age:** Valproic acid or sodium valproate, like certain other anti-convulsants, have been shown to be teratogenic in animals. In women of childbearing age, the benefits of these compounds should be weighed against the possible hazard suggested by these findings.

#### Further Information

When plasma valproic acid is within the recommended range of 50-120mg/litre (350-840µmol/litre) and serum albumin levels are normal, about 90% of the drug is bound to albumin. If the total plasma valproic acid rises above the upper range of normal, or if there is hypoalbuminaemia, the percentage of free valproic acid may rise markedly in proportion to any dosage increase and may be associated with a higher incidence of adverse effects.

#### Product Licence Numbers, Names and Addresses

Epilim 200 enteric-coated tablets 0623/0006  
Epilim Tablets 0623/0001  
Epilim 500 enteric-coated tablets 0623/0005  
Epilim Syrup 0623/0004

#### NHS Cost

Epilim 200 enteric-coated tablets 100, £7.04  
Epilim 500 enteric-coated tablets 100, £17.60  
Epilim Syrup 200ml, £4.03  
Epilim 200mg tablets 100, £5.45

#### LABAZ: Sanofi UK Ltd

Regent House, Heaton Lane,  
Stockport SK4 1AG, Cheshire  
Telephone: 061-480 0895; 6/7-8

Additional Information is available from the Company



Additional information is available from LABAZ: Sanofi U.K. Ltd, Regent House Heaton Lane Stockport SK4 1AG

# For many grand mal patients



## a full, normal life under the protection of



sodium valproate

200 enteric-coated, 500 enteric-coated tablets; syrup.

# JOURNAL OF MENTAL DEFICIENCY RESEARCH

*Editor:* Dr B W Richards

THE JOURNAL OF MENTAL DEFICIENCY RESEARCH  
contains original research on medical and psychological problems  
relevant to mental subnormality.

**Recent articles include:**

*The Effect of Treatment on Mental and Psychomotor Development of Marasmic Infants according to Age of Admission.* J. M. Celedon, Diane Csaszar, Jennifer Middleton and Isidora de Andraca.

*Age and Mortality Trends in Residents of an Institute for the Mentally Handicapped.* B. W. Richards and A. Q. Siddiqui.

*Preferences in Attention to Visual Cues in Down Syndrome and Normal Children.* B. Stratford.

*Dental Asymmetry and Mental Retardation: A Comparison of Subjects with Mental Retardation Resulting from Prenatal or Postnatal Influences.* H. S. Barden

*Follow-up of Case of Advanced Survival and Trisomy 18.* Arabella Smith and Gesina M. den Dulk.

*A New Approach to the Treatment of Phenylketonuria.* O. E. Pratt.

*Extra Dicentric 15pter → q21|22 Chromosomes in Five Unrelated Patients with a Distinct Syndrome of Progressive Psychomotor Retardation, Seizures, Hyper-reactivity and Dermatoglyphic Abnormalities.* Maria Zannotti, A. Preto, Paola Rossi Giorvanardi and B. Dallapiccola.

Published quarterly by

**THE NATIONAL SOCIETY  
FOR  
MENTALLY HANDICAPPED CHILDREN AND ADULTS**

**123 Golden Lane, London EC1Y 0RT**

**Yearly Subscription £20.00**

**U.S.A. \$60.00**

**Presentation**  
 Madopar 62.5, 125 and 250 mg tablets.  
 Madopar 125 and 250 mg capsules.  
 Madopar 62.5, 125 and 250 mg sachets.  
 Madopar 62.5, 125 and 250 mg granules.  
 Madopar 62.5, 125 and 250 mg syrup.  
 Madopar 62.5, 125 and 250 mg oral solution.  
 Madopar 62.5, 125 and 250 mg injection.  
 Madopar 62.5, 125 and 250 mg suppositories.

**Indications**  
 Madopar is indicated in the treatment of Parkinson's disease.

**Dosage**  
 The dosage of Madopar should be adjusted to the clinical response of the patient. The usual dosage is 100-200 mg levodopa and 25-50 mg benserazide per day, divided into 2-4 doses.

**Contra-indications**  
 Madopar is contra-indicated in patients with a known hypersensitivity to levodopa or benserazide, and in patients with pheochromocytoma.

**Precautions**  
 Madopar should be used with caution in patients with a history of cardiovascular disease, hypertension, glaucoma, epilepsy, and in patients taking other drugs which may interact with levodopa or benserazide.

**Side-effects**  
 The most common side-effects of Madopar are nausea, vomiting, and dizziness. Other side-effects include headache, constipation, and urinary retention.

**Packings**  
 Madopar is available in various packings, including tablets, capsules, sachets, granules, syrup, oral solution, injection, and suppositories.

**Licence Numbers**  
 Madopar is licensed in the United Kingdom, France, Germany, Italy, Spain, and other countries.

**Basic NHS Cost**  
 Madopar is available on the NHS at a reduced price.


**References**  
 Madopar is mentioned in several medical journals and textbooks.



Roche Products (UK) Ltd., Welwyn Garden City, Herts. SG8 4NS, UK.  
 Madopar is a registered trademark of Roche.

# 4+1

*the right balance*



Mozart, in his Clarinet Quintet, achieved harmony with a balance of 4 + 1.

Roche, with Madopar, struck the right balance of 4 + 1 with levodopa and the decarboxylase inhibitor benserazide. Chosen from several ratios as the one giving the best results in clinical practice; this combination has proved its rightness over a decade of clinical experience.


The 4 + 1 preparation of levodopa and benserazide has recently added another string to its bow. In a comparative trial it was shown to be preferred by patients to a 10 + 1 preparation of levodopa and carbidopa because of its better gastro-intestinal tolerance in the critical first three months of treatment.

# Madopar

levodopa plus benserazide

*balanced for optimal performance in Parkinson's disease*

**62.5, 125 and 250**



## Disipal has made her a little more responsive to her phenothiazine therapy.

The addition of Disipal to phenothiazine therapy enables optimum therapeutic response to be achieved without unacceptable side effects. Disipal also elevates the patient's mood, thus relieving the depression so often associated with major tranquillizer therapy.

### Drug of choice

Following a three month double blind crossover trial, the authors concluded that, "orphenadrine is the drug of choice in the treatment of drug-induced extra-pyramidal reactions and depression."<sup>1</sup>

### Increased response

Furthermore, the authors postulate that "the introduction of orphenadrine in the treatment of a patient whose response to phenothiazines is not maintained, might well result in further benefit."<sup>1</sup>

## For patients on major tranquillizer therapy Disipal

- \* controls extra-pyramidal reactions
- \* elevates patient mood.


<sup>1</sup> Capstick N. J. Int. Med. Res. 1976; 4: 61-435. Disipal (orphenadrine hydrochloride B.P.) is a registered trademark.

Full prescribing information on request from:—

**Brocades (Great Britain) Ltd**

Brocades House, 15, Longwalk Road, Egham, Surrey, TW20 1EX  
Telephone: 0370 415354/2241. Telex: 91126

# MS6 The most versatile electrophysiological system



The Medelec MS6 System has been specially designed on the modular principle for a wide range of applications in research, diagnosis and teaching.

It is based on the MS6 Display and Fibre Optic Recording Unit which displays the acquired signals and produces inexpensive daylight developed paper records for a wide range of plug-in modules which include stimulus generators, biological amplifiers, averagers, analysers and trigger/delay units.

Medelec also offer visual and auditory stimulators, a wide range of surface and needle electrodes for stimulation and signal acquisition and other accessories.

Applications for the MS6 System include:

#### **Electromyography**

Sensory and Motor Nerve Conduction Velocity  
Action Potential Analysis  
Somato Sensory Responses  
Single Fibre EMG

#### **Neuro-Ophthalmology**

Ocular Myography and Kinesis  
Electro-Retinography  
Electro-Oculography  
Visual Evoked Potentials

#### **Neuro-Otology**

Electrocochleography  
Brain Stem Responses  
Nystagmography  
Evoked Response Audiometry  
Facial Nerve Measurements

#### **Kinesiology**

Polygon Limb Angle Studies

**medelec**



A Vickers Medical Company

**MEDELEC LIMITED** Manor Way  
Woking Surrey GU22 9JU England  
Telephone: Woking (048 62) 70331  
Telex: 859141 Medlec G.

In North and South America make enquiries about comparable equipment to:  
Teca Corporation, 3 Campus Drive, Pleasantville, New York 10570, U.S.A.

# AN UPDATE ON CEREBRAL VASCULAR DISEASE

UNIVERSITY HOSPITAL, LONDON, ONTARIO, CANADA

28-30 OCTOBER 1981

**Co-Sponsored by:**

Canadian Stroke Society  
The Royal College of Physicians and Surgeons of Canada  
The Canadian Heart Foundation  
The Ontario Heart Foundation  
American Association of Neurological Surgeons  
Congress of Neurological Surgery  
College of Family Physicians of Canada

Z Ito, Japan  
Niels A Lassen, Copenhagen  
P Loiseau, Bordeaux  
J W Norris, Toronto  
F Plum, New York  
C W McCormick, Halifax  
B S Schoenberg, Bethesda

**Course Directors:**

H J M Barnett, C G Drake, V C Hachinski,  
S J Peerless

**UWO FACULTY**

H J M Barnett	V C Hachinski
H W K Barr	A Kertesz
P Cooper	S J Peerless
G Debrun	M D Silver
C G Drake	J D Spence
G G Ferguson	F Vinuela
A J Fox	

**GUEST FACULTY**

R H Ackerman, Boston  
C Fieschi, Rome  
E T Fossell, Boston

---

**WEDNESDAY, 28 OCTOBER 1981**

**STROKE I**

**Pathogenesis:**

The cerebral circulation.  
Peptides and the cerebral circulation.  
Cerebral ischemia.

**The Heart in Stroke and TIA:**

Cause, consequence or coincidence?  
The pathologic and clinical evidence.  
Non-arteriosclerotic heart disease in stroke and TIAs.

**Diagnosis:**

Clinical diagnosis—Radiological—Non-invasive.

**Horizons and limits in the treatment of cerebral ischaemia.**

**THURSDAY, 29 OCTOBER 1981**

**STROKE II**

**New Research Techniques:**

Nuclear magnetic resonance.  
Positron emitting tomography.  
Other research frontiers.

Blood velocity and atherosclerosis.

**Treatment:**

Intensive care of stroke.  
Corticosteroids in stroke.  
Mechanisms of brain recovery.

**Prevention:**

Managing TIAs.  
Controlling risk factors.

**Stroke and Epilepsy.**

**FRIDAY, 30 OCTOBER 1981**

**Neurovascular Surgery:**

Managing aneurysms.  
Complications of aneurysm surgery.  
Carotid endarterectomy.

**Uncertainties in the Prevention and Management of Cerebral Vascular Disease:**

Intracerebral hemorrhage—medical or surgical treatment?

**Interventional Radiology:**

Carotid cavernous fistulae.  
Arterio-venous malformations.  
Aneurysms.

Some controversies in neurovascular surgery.  
Extracranial/intracranial bypass surgery.  
Asymptomatic bruits, stenoses and steals.

(There will be a panel discussion at the end of each half day)

*Further information and registration forms available:*

Dr V C Hachinski, RM 1-3 University Hospital, PO Box 5339, Stn A, London, Ontario, Canada N6A 5A5

---



# Neurological Research

*An Interdisciplinary Quarterly Journal*

George M. Austin, *Editor*

This important new journal emphasizes an interdisciplinary approach to problems of neurology and neurological science. Subjects covered include neurology, neurological surgery, psychobiology, biomathematics, neuropathology, biochemistry, physiology, and cybernetics.

The Editorial Board is comprised of scientists who have been innovators in the development of new ideas and techniques for the solution of clinical and neurological problems. Full-length research papers as well as shorter research papers, technical reports, and review articles are included in the journal.

*Selected articles from the first issue*

Intraluminal Diameters of Middle Cerebral Branches for Microanastomosis • Biomathematical Models of Schizophrenia • Measurement of the Hydrostatic Pressures of the Cochlear Compartments • The Role of Extracellular Potassium in Early Epilepsy.

*Issued quarterly / Volume 1 \$76.00*

Butterworth (Publishers) Inc.

10 TOWER OFFICE PARK WOBURN, MASSACHUSETTS 01801

BRITISH POSTGRADUATE MEDICAL FEDERATION—UNIVERSITY OF LONDON

# INSTITUTE OF NEUROLOGY

(QUEEN SQUARE, LONDON WC1N 3BG)

ASSOCIATED WITH THE NATIONAL HOSPITAL, QUEEN SQUARE, AND THE  
HOSPITAL FOR NERVOUS DISEASES, MAIDA VALE

The Institute offers postgraduate training in the various neurological disciplines, as well as running whole-time 10 week courses of instruction during the Autumn, Winter and Spring terms. Fee and further details available on application to the Administrative Officer, Institute of Neurology.

Application should be made to the Dean at the Institute, Dr. P. C. GAUTIER-SMITH

## Fibrinolysis and its Inhibition

*The Proceedings of a Symposium organised by the  
Royal College of Pathologists*

**Edited by J. F. Davidson**

**Scientific basis**—Biological role of fibrinolysis ● Biochemistry of the plasmin system ● Breakdown products of fibrin and fibrinogen: molecular mechanisms and clinical implications ● Plasminogen activators: a morphologist's view ● Natural inhibitors of fibrinolysis ● Pathophysiology of intravascular coagulation and fibrinolysis ● **Therapeutic considerations**—Basis of antifibrinolytic therapy ● Clinical pharmacology of aminocaproic and tranexamic acids ● Assessment of inhibitors with chromogenic substrates ● **Clinical applications**—Inhibitors of fibrinolysis in the treatment of haemophilia ● Clinical applications of fibrinolytic inhibition in gynaecology ● Antifibrinolytic therapy in genitourinary tract surgery ● Fibrinolysis and gastrointestinal haemorrhage ● Tranexamic acid (AMCA) in aneurysmal subarachnoid haemorrhage ● Adjuvant treatment of ovarian carcinoma with tranexamic acid ● Future prospects for use of fibrinolysis inhibitors.

**Price: Inland £5.00; Abroad US\$12.50, including postage**

Payment must be enclosed with order or a surcharge of 50p will be made for rendering invoices and statements

ORDER YOUR COPY NOW FROM: The Publisher, *Journal of Clinical Pathology*, B.M.A. House, Tavistock Square, London WC1H 9JR

# EPIDEMIOLOGY FOR THE UNINITIATED

Do you know the difference between the incidence of a disease and its prevalence? How to set up a valid controlled trial? How to plan and conduct a survey? Many doctors would like to carry out some simple clinical research but find they lack basic information of this kind. The answers were published in 1978-79 in a series of *BMJ* articles, now collected together in book form essential reading for anyone contemplating starting a research study.


Price: Inland £2.50,  
Abroad US\$6.25

(Concessionary price to BMA  
members: Inland £2.00  
Abroad US\$5.00)

When ordering BMA members must  
quote their membership number or  
the full price will be applicable.

Payment must be enclosed with order or a cheque of 50p will be made to tender by invoice and statement.

**Order your copy now**  
From: The Publisher  
British Medical Journal  
BMA House  
Tavistock Square  
London WC1H 9JR  
*or any leading bookseller*





## NEW Mk. 4 E.C.T. APPARATUS DUOPULSE, ECTONUSTIM, ECTONUS & ECTRON

ALSO

## SOMLEG ELECTRO SLEEP APPARATUS

Send for full details

## ECTRON LTD

Knap Close Letchworth Herts SG6 1AQ England

Telephone LETCHWORTH 2124

Cables ECTRON LETCHWORTH

### New from Pitman

#### Research Progress in Parkinson's Disease

Edited by Rudy Capildeo and F. Clifford Rose

A review of the recent advances in knowledge of all aspects of Parkinsonism and the likely avenues for further research. The contributors are internationally acknowledged in this field.

March 1981/ISBN 0 272 79601 8/Cased/£25.00

#### Neurological Therapeutics

D. L. W. Davidson and J. A. R. Lenman

The authors have drawn together views on the therapy of neurological disorders to provide a useful exposition in current treatment suitable for neurologists in training, physicians in hospital and general practitioners.

May 1981/ISBN 0 272 79616 6/Cased/£14.95

#### Development of the Autonomic Nervous System

Ciba Foundation Symposium 83

In this international symposium development biologists and clinicians discuss how the autonomic nervous system develops, both normally and in pathological conditions, as revealed by tissue culture, by observations *in vivo* of embryological and perinatal development and by regeneration and transplantation experiments.

July 1981/ISBN 0 272 79619 0/Cased/£19.50

Place an order now with your bookseller, or in case of difficulty from the publisher through Book Centre, Southport PR9 9YF.

Pitman Books Limited, 39 Parker Street, London WC2B 5PB

## Pitman Books